Skip to main content
SpringerLink
Log in

Therapeutic Benefits and Safety of Carvedilol in the Treatment of Renal Hypertension

An Open, Short Term Study

  • Studies in Special Patient Group
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Carvedilol, a new β-blocker with vasodilating activity, was given orally to 9 hypertensive inpatients with impaired renal function in a dosage regimen of 5 to 20mg once daily to evaluate its clinical efficacy and safety.

Treatment with carvedilol produced a significant decrease in blood pressure from 172/ 101 to 150/87 mm Hg (p < 0.01), but it did not cause orthostatic hypotension. Heart rate was decreased from 74.3 to 72.8 beats/min, but the decrease was not statistically significant. Serum creatinine and BUN levels were unchanged and other laboratory parameters were within normal limits. There were no side effects in any of the patients during the trial.

These results suggest that carvedilol is a useful and safe drug for the treatment of renal hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bauer JH, Brooks CH. The long-term effect of propranolol therapy on renal function. American Journal of Medicine 66: 405–410, 1979

    Article  PubMed  CAS  Google Scholar 

  • Cowley AW, Roman RJ. Renal dysfunction in essential hypertension. Implications of experimental studies. American Journal of Nephrology 3: 59–72, 1983

    Article  PubMed  Google Scholar 

  • Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, et al. Clinical pharmacology of carvedilol in normal volunteers. Clinical Pharmacology and Therapeutics 41: 31–44, 1987

    Article  PubMed  CAS  Google Scholar 

  • De Leeuw PW, Birkenhäger WH. Renal effects of beta blockade in essential hypertension. European Heart Journal 4 (Suppl. D): 13–17, 1983

    PubMed  Google Scholar 

  • Emery AC, Whitcomb W, Frohlich ED. ‘Stress’ polycythemia and hypertension. Journal of the American Medical Association 229: 159–162. 1974

    Article  PubMed  Google Scholar 

  • Eggertsen R, Sivertsson R, Andrén L, Hansson L. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. Journal of Hypertension 2: 529–534, 1984

    Article  PubMed  CAS  Google Scholar 

  • Falch DK, Degaard AE, Norman N. Decreased renal plasma flow during propranolol treatment in essential hypertension. Acta Medica Scandinavica 205: 91–95, 1979

    Article  PubMed  CAS  Google Scholar 

  • Hakusui H, Fujimaki M, Igarashi S, Ajima H, Yamamura H. Pharmacokinetics of a new beta blocker DQ-2466 (carvedilol) in normal man. Japanese Journal of Clinical Pharmacology 17: 11–12, 1986

    Article  Google Scholar 

  • Hollenberg NK, Adams DF. The renal circulation in hypertensive disease. American Journal of Medicine 60: 773–784, 1976

    Article  PubMed  CAS  Google Scholar 

  • Irie K, Takasuna K, Kunitada S, Mori T, Ashida S, et al. Hemodynamic profile of carvedilol, a new beta-adrenoceptor blocking agent with vasodilator properties, in conscious SHR. Japanese Journal of Pharmacology 43 (Suppl.): 142P, 1987

    Google Scholar 

  • Ishii M. Calcium antagonists. Clinical Research 61: 3462, 1985

    Google Scholar 

  • Lazarus JM, Hypertension in chronic renal failure. Archives of Internal Medicine 133: 1059, 1974

    Article  PubMed  CAS  Google Scholar 

  • Leth A, Ibsen H. Changes in the ratio of plasma to interstitial fluid volume during long-term antihypertensive therapy. Journal of Laboratory and Clinical Medicine 87: 781–791, 1976

    PubMed  CAS  Google Scholar 

  • Neugebauer G, Akpan W, Möllendorff VE, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S85–S88, 1987

    PubMed  CAS  Google Scholar 

  • Ogihara T, Ikeda M, Goto Y, Yoshinaga K, Kumahara Y, et al. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. Journal of Cardiovascular Pharmacology 10: (Suppl. 11): S108–S112, 1987

    PubMed  Google Scholar 

  • Onoyama K. Symposium on the etiology and treatment of hypertension (3) Hypertension in chronic glomerulonephritis. Japanese Journal of Medicine 21: 149, 1982

    Article  PubMed  CAS  Google Scholar 

  • Reubi FC. Role of physical factors in the acute changes in renal function elicited by antihypertensive drugs. European Journal of Clinical Pharmacology 13: 185–193, 1977

    Article  Google Scholar 

  • Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Böhm E. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypertensive properties. Journal of Cardiovascular Pharmacology 9: 317–327, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Sponer G, Strein K, Müller-Beckmann B, Bartsch W. Studies on the mode of vasodilating action of carvedilol. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S42–S48, 1987b

    PubMed  CAS  Google Scholar 

  • Tanaka M, Masumura H, Tanaka S, Akashi A. Studies on the antihypertensive properties of carvedilol, a compound with β-blocking and vasodilating effects. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S52–S57, 1987

    PubMed  CAS  Google Scholar 

  • Wilkinson R. Beta-blockers and renal function. Drugs 23: 195–206, 1982

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, Osaka City University Medical School, Abeno-ku, Osaka, 545, Japan

    Masakazu Kohno & Tadanao Takeda

Authors
  1. Masakazu Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadanao Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masao Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takao Saruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasushi Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manabu Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinichiro Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koshiro Fukiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masatoshi Fujishima
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Carvedilol Renal Hypertension Study Group in Japan

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohno, M., Takeda, T., Ishii, M. et al. Therapeutic Benefits and Safety of Carvedilol in the Treatment of Renal Hypertension. Drugs 36 (Suppl 6), 129–135 (1988). https://doi.org/10.2165/00003495-198800366-00022

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198800366-00022

Keywords

Search

Navigation